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Introduction
Somatostatin receptors have been demonstrated in the
brain, in the pituitary gland, and on endocrine
pancreatic islet cells (1, 2). These receptors may also
be expressed on mostly neuroendocrine tumours (3)
and in areas infested by certain immune-mediated
diseases (4±7). The presence or overexpression of
somatostatin receptors on these tumours and in these
diseases is used when in vivo somatostatin receptor
imaging (SRS) is performed in patients. A chelated,
radiolabelled somatostatin analogue, [111In-DTPA0]-
octreotide (OctreoScan, Mallinckrodt, Petten, the
Netherlands), was injected and images were made
after an interval of usually 24 h, which allows for
primarily urinary and also, to a very small extent,
hepatobiliary excretion. By then, background radio-
activity had dropped considerably. Normal scinti-
graphic features due to receptor binding include
visualization of the pituitary (to a variable degree),
the thyroid and the spleen, whereas visualization of
the liver, kidneys and urinary bladder mainly repre-
sents the metabolization of the radiopharmaceutical.
Because of the normal accumulation of radioactivity
in the above-mentioned organs, but especially in the
spleen, kidneys, and to a lesser degree in the liver, the
detection of somatostatin receptor-positive pathology
in or near these organs may be hampered. This may
be overcome by performing single photon energy
computed tomography but, in diseases with low
receptor density, the detection of lesions in the upper
abdomen may be difficult. If receptor density is high,
however, the recognition of lesions usually poses no
problems. Therefore, in neuroendocrine gastroentero-
pancreatic (GEP) tumours, which have a high receptor
density, SRS has been found to be more sensitive than
other imaging techniques, and is advocated as the
imaging technique of choice in the staging procedure
(8).
SRS may also demonstrate lesions in a number of
non-neuroendocrine tumours, such as, for instance,
breast carcinoma, Hodgkin's disease and non-Hodg-
kin lymphoma (NHL), and in immune-mediated
diseases like rheumatoid arthritis and granulomatous
diseases. However, its role in the diagnosis of these
diseases is very limited, and its value in staging and
monitoring the response to therapy remains to be
evaluated.
Localization of somatostatin receptors in
haematological and immune-mediated
disease and results of SRS
Somatostatin receptors have been demonstrated by
autoradiography with [125I-Tyr3]-octreotide on granu-
loma tissue (5). The receptors were located in the areas
containing epitheloid cells and not in the zone of
surrounding lymphocytes. However, a more precise
identification of the cells expressing somatostatin recep-
tors, using receptor antibodies, showed that macrophages
and epitheloid cells are the targets for receptor binding in
granulomatous diseases (6). It is also of interest that
biopsies that were negative for somatostatin receptor
staining were characterized by fibrosis and the absence of
an active monoclear infiltrate, indicating that receptor
expression may be correlated to active disease. Using in
vivo SRS in a cross-sectional study in 46 patients with
sarcoidosis, known mediastinal, hilar and interstitial
disease was recognized in 36 of 37 patients (9). Also,
such pathology was found in seven other patients who
had normal chest X-rays. In five of these, SRS indicated
interstitial disease. SRS was repeated in 13 patients. In
five of six patients who showed a chest X-ray-monitored
improvement in disease activity, SRS also showed a
decrease in pathologic uptake. In two of five patients in
whom the chest X-ray was unchanged, but serum
angiotensin converting enzyme concentrations were
decreased and lung function was improved, a normal-
ization was found on octreotide scintigrams. To deter-
mine the value of SRS in the follow-up of patients with
sarcoidosis a prospective longitudinal study will have to
be performed.
In the synovial membranes of patients with rheumatoid
arthritis, high affinity binding of [125I-Tyr3]-octreotide has
been shown (4). With receptor antibodies, staining for
somatostatin subtype 2 receptors was found on a macro-
phage subset (7). In vivo, 76% of disease-affected joints in
patients with rheumatoid arthritis were visualized with
SRS (Figs 1 and 2). The degree of pain and swelling
correlated with positive scintigraphic findings (4).
With autoradiography, somatostatin receptors have
been demonstrated on human lymphomas (10±12).
Although in many patients with NHL one or more lesion
may be somatostatin receptor-positive (Fig. 3), receptor-
negative lesions also occur in a substantial number of
patients (11). Therefore, the diagnostic role for SRS in
patients with NHL is limited. In 56 consecutive untreated
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patients with histologically proven Hodgkin's disease the
results of SRS were compared with physical and
radiological examinations (12). SRS was positive in 55
of 56 (98%) patients at the sites of documented disease.
In 20 patients, SRS disclosed lymphoma localizations not
revealed following procedures for conventional staging.
As a result, in 12 patients (21%), SRS produced a change
of stage and in seven patients (13%) the additional
information led to a change of treatment. Therefore, SRS
seems to be promising in the clinical staging and
management of patients with Hodgkin's disease.
Peptide receptor radionuclide therapy
(PRRT), a sequel to SRS
In patients with end-stage progressive neuroendocrine
tumours which, in the majority, showed a high uptake of
[111In-DTPA0]-octreotide during in vivo SRS, radio-
nuclide therapy with high doses of [111In-DTPA0]-
octreotide was performed in a phase-1 study. In 30
patients who received up to a cumulative dose of 74 GBq,
the side-effects were a (transient) decline in platelet
counts and lymphocyte subsets. Of the 21 patients who
received a cumulative dose of more than 20 GBq, a
reduction in tumour size was found in six, and stable
disease in eight. There was a tendency towards better
results in patients with a high tumour uptake (13).
111In-coupled peptides, because of their small par-
ticle range, and therefore short tissue penetration, are
not the ideal radiopharmaceuticals for radionuclide
therapy. Recently, another somatostatin analogue,
[DOTA0, Tyr3]-octreotide (DOTATOC), has been devel-
oped, to which the b-emitter 90Y can be linked in a very
stable manner (14). In a recent study (15), the uptake
of radioactivity in known somatostatin receptor-posi-
tive organs and tumours was higher after 111In-
DOTATOC than after [111In-DTPA0]-octreotide. A
recent preliminary study by Otte et al. (16) showed
favourable results of 90Y-DOTATOC treatment in five
patients with neuroendocrine tumours. Also, a study
has been started in our hospital comparing both the
uptake of 111In-DOTATOC and 86Y-DOTATOC, as well
as the effects of treatment with 90Y-DOTATOC in the
same patients. Because the kidney is the dose-limiting
organ in PRRT with 90Y-DOTATOC, an infusion of
amino acids is given during and after the infusion of the
radiopharmaceutical, in order to reduce the kidney
uptake. A recent analysis of the results of this treatment
in 22 end-stage patients with progressive disease shows
a partial tumour response in two, a minor response in
three, and stable disease in ten patients (17).
Because of favourable results in terms of tumour
regression in animals after therapy with another
somatostatin analogue, [177Lu-DOTA,Tyr3]-octreotate
(18), the first injections of 1850 MBq of this radio-
pharmaceutical were very recently given to six patients
in our hospital. A preliminary comparison with [111In-
DTPA0]-octreotide points to a higher tumour uptake,
whereas the kidney uptake for both radiopharma-
ceuticals is the same. This implies that the radio-
therapeutical dose to the tumour potentially increases
with [177Lu-DOTA,Tyr3]-octreotate, given a fixed
maximum kidney dose. In addition, the application of
Figure 1 SRS in a patient with arthritis, 24 h post-injection. Lateral
images of the head (upper row), and anterior view of the chest, and
detail of the wrists and hands (lower row). Pathological uptake in
both wrists and also in the myocardium are shown.
Figure 2 SRS in a patient with arthritis, 24 h post-injection. Anterior
and posterior views of the head (upper row), and upper and lower
extremities (lower row). Normal uptake in the pituitary and thyroid
(upper left image) and pathological uptake in the right wrist (lower
left image) and both knees (lower right image) are shown.
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[177Lu-DOTA,Tyr3]-octreotate, which emits both
gamma and beta rays, allows dosimetry and therapy
with the same radiopharmaceutical.
Is PRRT a treatment option in patients
with haematological or immune-
mediated diseases?
Combination chemotherapy, external beam radiotherapy
and bone marrow transplantation, as single modality or
in combination, are the corner-stones of treatment for
Hodgkin's disease and NHL. High response and cure rates
are achieved, and the results of changing the therapeutic
strategies keep improving (19). As in patients with
neuroendocrine tumours, PRRT with radiolabelled soma-
tostatin analogues might be applied in patients with
Hodgkin's disease or NHL if the tumour uptake is
sufficient. In patients with neuroendocrine tumours, the
results of PRRT are better if the tumour uptake equals the
uptake in the liver or is greater. In patients with
lymphomas, however, the majority have a lower tumour
uptake. In addition, it should be realized that lymphoma
patients who have shown to be refractory to standard and
salvage chemotherapy and radiotherapy may very well
have developed bone marrow and renal toxicity, which are
also the two most important potential side-effects of PRRT.
Also, as a rule, little benefit can be expected from PRRT if
previous external beam radiotherapy in these patients did
not affect tumour growth. Finally, in most patients with
therapy-refractory lymphomas disease progression is fast;
with the present treatment schemes of PRRT, the dose
delivery to the tumour may therefore be too slow. Despite
all these arguments against its use, PRRT could be tried in
some patients who fail to respond to `standard' therapy on
the condition that there is a high tumour uptake.
Therapy in patients with sarcoidosis is symptomatic.
Because of the high rate of spontaneous remission in
patients with limited disease stages, corticosteroid
treatment is best reserved for patients with active
pulmonary sarcoidosis or patients with pulmonary
function impairment, dyspnea, cough, chest pain,
hypercalcaemia or extrapulmonary organ involvement
Figure 3 SRS in a patient with NHL, 24 h post-injection. Lateral views of the head (upper row) with normal uptake in the pituitary and
pathological uptake at the site of a lymphoma in the left neck are shown. Anterior and posterior view of the chest (middle row), showing
that the lymphoma uptake is comparable to (normal) uptake in the liver (bottom row). Normal, intense uptake in the spleen can also be
seen (bottom row). The left two columns are scaled to allow for good visualization of the lymphoma. The right two columns are scaled to
allow for comparison of the uptake in the lymphoma and in the liver.
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(20, 21). Because somatostatin subtype 2a receptors in
granulomas were found on macrophages and epithelioid
cells (6) and on a macrophage subset in the synovium
from patients with rheumatoid arthritis (7), PRRT with
radiolabelled somatostatin analogues, if effective, will
probably affect these constituents of the inflammation.
In vitro, the inhibition of cytokine release from
monocytes (22) and diminished granuloma size in a
mouse schistosomiasis model (23) by octreotide were
demonstrated. Whether PRRT may lead to a decrease of
the inflammatory response and of granuloma size in
patients is, at this moment, speculative.
In patients with refractory rheumatoid arthritis,
so-called `radiosynoviorthesis' or `radiosynovectomy'
with b-emitting radionuclides (mostly 90Y) may cause
symptomatic relief in the treated joints (24, 25). Usually,
depending on the size of the joints to be treated, 37±
185 MBq are injected intra-articularly, resulting in up to
about 100 Gy (10 000 Rad) radiation-absorbed dose.
Because only a limited number of joints can be treated
with this method, the advantage of PRRT, resulting in
radiation to all joints that show uptake, seems evident.
The degree of uptake of radioactivity during SRS in
rheumatoid joints is usually low, however, as is usually
the case in granulomatous lesions. It may therefore be
questioned whether a sufficient dose can be delivered.
On the other hand, if PRRT selectively affects the cells
that are responsible for the immune response, such
lower doses could be sufficient.
As mentioned previously, PRRT may cause bone
marrow and renal toxicity. Such side-effects will have to
be weighed against the possible benefits of treatment.
PRRT should therefore, in our opinion, only be tried in
patients with invalidating, progressive granulomatous
disease or rheumatoid arthritis who are refractory to
other treatments.
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